Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents

Author： Zimarino Marco   Renda Giulia   Raffaele De Caterina  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.65, Iss.6, 2005-01, pp. : 725-732

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deciphering Dual Antiplatelet Therapy in the Era of Drug-Eluting Coronary Stents

By  

Current Drug Targets, Vol. 10, Iss. 6, 2009-06 ,pp. : 519-529

Bentham Science Publishers

Access to resources Recommend Favorite

Use of Antiplatelet Therapy after Percutaneous Coronary Intervention with Bare-Metal Stents and Different Types of Drug-Eluting Stents

By  

Current Clinical Pharmacology, Vol. 8, Iss. 1, 2013-02 ,pp. : 59-66

Bentham Science Publishers

Access to resources Recommend Favorite

Poor Response to Antiplatelet Drugs. An Important Issue in Drug-Eluting Stents.

By  

Current Clinical Pharmacology, Vol. 8, Iss. 4, 2013-11 ,pp. : 340-349

Bentham Science Publishers

Access to resources Recommend Favorite

Drug-Eluting Stents

By  

Heart Drug, Vol. 3, Iss. 4, 2004-02 ,pp. : 203-213

Karger

Access to resources Recommend Favorite

Drug Eluting Coronary Artery Stents

By  

Current Drug Delivery, Vol. 7, Iss. 5, 2010-12 ,pp. : 421-427

Bentham Science Publishers

Access to resources Recommend Favorite